99mTc-Ibandronate as Imaging Radiopharmaceutical for Early Detection of Bone Diseases | ||
| Bulletin of Faculty of Science, Zagazig University | ||
| Articles in Press, Accepted Manuscript, Available Online from 17 October 2020 | ||
| Document Type: Original Article | ||
| DOI: 10.21608/bfszu.2020.37131.1032 | ||
| Author | ||
| mohammed salah soliman* | ||
| Chemistry department, faculty of science, Helwan university | ||
| Abstract | ||
| Ibandronate was successfully labeled by using technetium-99m with maximum radiochemical yield (98.6%). The process is achieved by adding (25 µg) from stannous chloride in addition to (300 µg) of Ibandronate at room temperature in pH=7 for 15 min., we obtain a radiochemical yield (98.6%) and the radiolabeled complex was purified by high performance liquid chromatography (HPLC). The radiochemical yield was affected by many factors such as: Ibandronate amount, stannous chloride amount, reaction time, temperature of the reaction and pH of the reaction mixture. The in-vitro stability of 99mTc-Ibandronate was determined along (8 hours). The data obtained approve that 99mTc-Ibandronate complex was stable along (6 hours) without detection of any by-products in the reaction mixture. Biodistribution study showed high uptake and long retention of 99mTc-Ibandronate in bone was (44.32 % ID/organ) at (1 hour) post injection. Thus, 99mTc–Ibandronate could be used as a selective potential imaging agent for diagnosis of bone diseases | ||
| Keywords | ||
| Ibandronate; technetium-99m; bone diseases; Radiopharmaceutical | ||
|
Statistics Article View: 201 |
||
